Medigene AG Announces Lead Selection for MDG2011 Representing the First TCR-T Therapy of its KRAS Library

Medigene AG announced that it has selected its lead candidate for MDG2011, a T cell receptor engineered T cell (TCR-T) therapy targeting KRAS G12V with HLA-A*11 and being developed in combination with the Company’s PD1-41BB costimulatory switch protein technology.